Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

BlueEarthTherapeutics

More Like This

PR Newswire associated0

Blue Earth Therapeutics Reports Key Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial

PR Newswire associated0

Blue Earth Therapeutics initiates Phase 2 Clinical Trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-10.1 Injection in metastatic castrate resistant prostate cancer

PR Newswire associated0

Blue Earth Therapeutics Ltd announces completion of $76.5M Series A financing to accelerate development of next generation targeted radioligand therapies

Blue Earth Therapeutics Announces Clinical Research Collaboration with UCL to Develop Innovative Alpha-labelled Radioligand Therapy (RLT) for Prostate Cancer

Blue Earth Therapeutics Ltd Announces Expansion of Partnership With Seibersdorf Labor GmbH to Include Manufacture of Therapeutic Radiopharmaceutical, 225Ac-rhPSMA-10.1

Blue Earth Diagnostics Ltd Collaborates with Sinotau Pharmaceutical Group to Bring Prostate Cancer PET Diagnostic Imaging Agent, Flotufolastat (18F) Injection, to China

PR Newswire associated0

NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports

Philochem and Blue Earth Diagnostics Announce First Three Patients Imaged in Phase 1 Clinical Trial of 68Ga-OncoFAP (68Ga-OncoFAP-DOTAGA) for Diagnostic Imaging in Solid Tumors